MENU
CLOSE
Sign Up
Donate
Understanding Multiple Myeloma
Multiple Myeloma in Underserved Populations
Navigating Diagnosis & Treatment
Building The Right Treatment Team
Diagnostic Testing for Multiple Myeloma
Treatments for Multiple Myeloma
Clinical Trials and Emerging Therapies for Multiple Myeloma
Finding Support
Patient Navigation Center
MMRF Myeloma Mentors
Patient & Caregiver Support
Financial, Transportation, & Other Resources
Patient Stories
Education Resource Hub
Myeloma Glossary
Finding a Cure
Accelerate the Development of Novel Therapies
Drive Personalized Treatment Approaches
Empower Patients and the Community
Get Involved
Fundraise for the MMRF-old
Walk/Run Program
Moving Mountains for Multiple Myeloma
Marathon/Half Marathon
Biking/Road to Victories
Create Your Own Fundraiser
About Us
Our Founders’ Story
Our Impact
DEIB
Accreditations & Financial Reports
Executive Leadership
Scientific Advisory Board
Board of Directors
Our Sponsors
News & Publications
News & Events
Home
>
Addressing Key Questions About BCMA-Targeted Therapy for Relapsed/Refractory Multiple Myeloma (CME-accredited activity)
Addressing Key Questions About BCMA-Targeted Therapy for Relapsed/Refractory Multiple Myeloma (CME-accredited activity)
